Growth Metrics

Pfizer (PFE) Cash from Investing Activities (2016 - 2025)

Pfizer (PFE) has disclosed Cash from Investing Activities for 17 consecutive years, with -$6.1 billion as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities changed N/A to -$6.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 billion through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.4 billion for FY2025, 150.94% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$6.1 billion at Pfizer, down from -$2.4 billion in the prior quarter.
  • The five-year high for Cash from Investing Activities was $4.6 billion in Q2 2024, with the low at -$25.5 billion in Q3 2023.
  • Average Cash from Investing Activities over 5 years is -$4.4 billion, with a median of -$1.7 billion recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 2359.15% in 2021, then soared 484.66% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$20.0 billion in 2021, then surged by 43.02% to -$11.4 billion in 2022, then grew by 3.31% to -$11.0 billion in 2023, then skyrocketed by 138.88% to $4.3 billion in 2024, then crashed by 243.77% to -$6.1 billion in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$6.1 billion, -$2.4 billion, and $4.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.